Mary-Claire Roghmann

Mary-Claire Roghmann

Auto-generated profile, based on publicly available information

Mary-Claire Roghmann

VA Maryland Health Care System- Baltimore VA Medical Center , Baltimore, MD

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
NSNimalie D. Stone
Nimalie D. Stone
MAMuhammad S. Ashraf
Muhammad S. Ashraf
JCJennifer Calder
Jennifer Calder
CCChristopher J. Crnich
Christopher J. Crnich
KCKent Crossley
Kent Crossley
SGSociety for Healthcare Epidemiology Long-Term Care Special Interest Group
Society for Healthcare Epidemiology Long-Term Care Special Interest Group
Infection surveillance definitions for long-term care facilities (ie, the McGeer Criteria) have not been updated since 1991. An expert consensus panel modified these definitions on the basis of a structured review of the literature. Significant changes were made to the criteria defining urinary tract and respiratory tract infections. New definitions were added for norovirus gastroenteritis and Clostridum difficile infections.Infect Control Hosp Epidemiol 2012;33(10):965-977

1 March 2007 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
SSSimone Shurland
Simone Shurland
MZMin Zhan
Min Zhan
DBDouglas D. Bradham
Douglas D. Bradham
MRMary-Claire Roghmann
Mary-Claire Roghmann
Objective.: To quantify the clinical impact of methicillin-resistance in Staphylococcus aureus causing infection complicated by bacteremia in adult patients, while controlling for the severity of patients' underlying illnesses.Design.: Retrospective cohort study from October 1, 1995, through December 31, 2003.Patients and Setting.: A total of 438 patients with S. aureus infection complicated by bacteremia from a single Veterans Affairs healthcare system.Results.: We found that 193 (44%) of the 438 patients had methicillin-resistant S. aureus (MRSA) infection and 114 (26%) died of causes attributable to S. aureus infection within 90 days after the infection was identified. Patients with MRSA infection had a higher mortality risk, compared with patients with methicillin-susceptible S. aureus (MSSA) infections (relative risk, 1.7 [95% confidence interval, 1.3-2.4]; P < .01), except for patients with pneumonia (relative risk, 0.7 [95% confidence interval, 0.4-1.3]). Patients with MRSA infections were significantly older (P < .01), had more underlying diseases (P = .02), and were more likely to have severe sepsis in response to their infection (P < .01) compared with patients with MSSA bacteremia. Patients who died within 90 days after S. aureus infection was identified were significantly older (P < .01) and more likely to have severe sepsis (P < .01) and pneumonia (P = .01), compared with patients who survived. After adjusting for age as a confounder, comorbidities, and pneumonia as an effect modifier, S. aureus infection-related mortality remained significantly higher in patients with MRSA infection than in those with MSSA infection, among those without pneumonia (hazard ratio, 1.8 [95% confidence interval, 1.2-3.0]); P < .01.Conclusions.: The results of this study suggest that patients with MRSA infections other than pneumonia have a higher mortality risk than patients with MSSA infections other than pneumonia, independent of the severity of patients' underlying illnesses.

1 December 2005 in Critical Care Medicine
Verified
Journal Article
Closed access
BWBrian W. Whitcomb
Brian W. Whitcomb
EPElizabeth Kimbrough Pradhan
Elizabeth Kimbrough Pradhan
APAnastassios G. Pittas
Anastassios G. Pittas
MRMary-Claire Roghmann
Mary-Claire Roghmann
EPEli N. Perencevich
Eli N. Perencevich
Hyperglycemia in intensive care unit patients has been associated with an increased mortality rate, and institutions have already begun tight glucose control programs based on a limited number of clinical trials in restricted populations. This study aimed to assess the generalizability of the association between hyperglycemia and in-hospital mortality in different intensive care unit types adjusting for illness severity and diabetic history. Retrospective cohort study. The medical, cardiothoracic surgery, cardiac, general surgical, and neurosurgical intensive care units of the University of Maryland Medical Center. Patients admitted between July 1996 and January 1998 with length of stay ≥24 hrs (n = 2713). On intensive care unit admission, blood glucose and other physiologic variables were evaluated. Regular measurements were taken for calculation of Acute Physiology and Chronic Health Evaluation III scoring. Patients were followed through hospital discharge. Admission blood glucose was used to classify patients as hyperglycemic (>200 mg/dL) or normoglycemic (60–200 mg/dL). The contribution of hyperglycemia to in-hospital mortality stratified by intensive care unit type and diabetes history while controlling for illness severity was estimated by logistic regression. The adjusted odds ratios for death comparing all patients with hyperglycemia to those without were 0.81 (95% confidence interval, 0.37, 1.77) and 1.76 (95% confidence interval, 1.23, 2.53) for those with and without diabetic history, respectively. Higher mortality was seen in hyperglycemic patients without diabetic history in the cardiothoracic, (adjusted odds ratio, 2.84 [1.21, 6.63]), cardiac (adjusted odds ratio, 2.64 [1.14, 6.10]), and neurosurgical units (adjusted odds ratio, 2.96 [1.51, 5.77]) but not the medical or surgical intensive care units or in patients with diabetic history. The association between hyperglycemia on intensive care unit admission and in-hospital mortality was not uniform in the study population; hyperglycemia was an independent risk factor only in patients without diabetic history in the cardiac, cardiothoracic, and neurosurgical intensive care units.

1 June 2003 in Emerging Infectious Diseases
Verified
Journal Article
Open access
MMMargaret E. McCusker
Margaret E. McCusker
AHAnthony D. Harris
Anthony D. Harris
EPEli Perencevich
Eli Perencevich
MRMary-Claire Roghmann
Mary-Claire Roghmann
We performed a case-control study to evaluate the association between antibiotic use and Clostridium difficile–associated diarrhea (CDAD), matching for admission unit and time at risk for CDAD. A multivariable regression model showed that treatment with fluoroquinolones (odds ratio 12.7; 95% confidence interval 2.6 to 61.6) was the strongest risk factor for CDAD.

17 February 2005 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
JMJessina C. McGregor
Jessina C. McGregor
PKPeter W. Kim
Peter W. Kim
EPEli N. Perencevich
Eli N. Perencevich
DBDouglas D. Bradham
Douglas D. Bradham
JFJon P. Furuno
Jon P. Furuno
AHAnthony D. Harris
Anthony D. Harris
Comorbidity is a known risk factor for antibiotic-resistant bacterial infections. Although aggregate comorbidity measures are useful in epidemiologic research, none of the existing measures was developed for use with this outcome. This study compared the utility of two comorbidity measures, the Charlson Comorbidity Index and the Chronic Disease Score, in assessing the comorbidity-attributable risk of nosocomial infections with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant enterococci (VRE). Two case-control studies were conducted at the University of Maryland Medical System in Baltimore, Maryland. Cases were inpatients with a first positive clinical culture of MRSA or VRE at least 48 hours postadmission (July 1, 1998–July 1, 2001). Three inpatient controls were randomly selected per case. The MRSA study included 2,164 patients, and the VRE study included 1,948. The scores’ discrimination and calibration were measured by using the c statistic and Hosmer-Lemeshow chi-square test. The Charlson Comorbidity Index (c = 0.653) and Chronic Disease Score (c = 0.608) were similar discriminators of MRSA and VRE (c = 0.670 and c = 0.647, respectively). Calibration of the scores was poor for both outcomes (p < 0.05). A revised comorbidity measure specific to resistant infections would likely provide a better assessment of the comorbidity-attributable risk of antibiotic-resistant infections.

1 October 2008 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
GFGraeme N. Forrest
Graeme N. Forrest
MRMary-Claire Roghmann
Mary-Claire Roghmann
LTLatoya S. Toombs
Latoya S. Toombs
JJJennifer K. Johnson
Jennifer K. Johnson
EWElizabeth Weekes
Elizabeth Weekes
RVRichard A. Venezia
Richard A. Venezia
Hospital-acquired vancomycin-resistant enterococcal bacteremia has been associated with increased hospital costs, length of stay, and mortality. The peptide nucleic acid fluorescent in situ hybridization (PNA FISH) test forEnterococcus faecalisand other enterococci (EFOE) is a multicolor probe that differentiatesE. faecalisfrom other enterococcal species within 3 h directly from blood cultures demonstrating gram-positive cocci in pairs and chains (GPCPC). A quasiexperimental study was performed over two consecutive years beginning in 2005 that identified GPCPC by conventional microbiological methods, and in 2006 PNA FISH was added with a treatment algorithm developed by the antimicrobial team (AMT). The primary outcome assessed was the time from blood culture draw to the implementation of effective antimicrobial therapy before and after PNA FISH. The severity of illness, patient location, and empirical antimicrobial therapy were measured. A total of 224 patients with hospital-acquired enterococcal bacteremia were evaluated, with 129 in the preintervention period and 95 in the PNA FISH period. PNA FISH identifiedE. faecalis3 days earlier than conventional cultures (1.1 versus 4.1 days;P< 0.001). PNA FISH identifiedEnterococcus faeciuma median 2.3 days earlier (1.1 versus 3.4 days;P< 0.001) and was associated with statistically significant reductions in the time to initiating effective therapy (1.3 versus 3.1 days;P< 0.001) and decreased 30-day mortality (26% versus 45%;P= 0.04). The EFOE PNA FISH test in conjunction with an AMT treatment algorithm resulted in earlier initiation of appropriate empirical antimicrobial therapy for patients with hospital-acquiredE. faeciumbacteremia.